Top-line results from KALM-2, the second of two Phase III studies of Cara Therapeutics Inc.'s pruritus therapy, Korsuva (CR845/difelikefalin), have confirmed the efficacy of the intravenous therapy to treat the condition in patients with chronic kidney disease on dialysis.
Results from the first Phase III trial, KALM-1, outlined in May 2019, were favorably received by analysts, who said they
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?